Request

Almaden Provides Corporate Update

Retrieved on: 
Thursday, March 14, 2024
Comprehensive, CPTPP, Consultation, Notice, AAU, AMM, Tribunal, Security (finance), Request, TSX, OTCQB, Government, Cryptocurrency

Accordingly, on March 14, 2024, Almaden delivered to Mexico written notice of its intention to submit a claim (“Claim”) to arbitration against Mexico (the “Notice”) in accordance with Article 9.19.3 of the CPTPP.

Key Points: 
  • Accordingly, on March 14, 2024, Almaden delivered to Mexico written notice of its intention to submit a claim (“Claim”) to arbitration against Mexico (the “Notice”) in accordance with Article 9.19.3 of the CPTPP.
  • This Notice has been delivered by Almaden together with Almadex Minerals Ltd., on behalf of themselves and their Mexican subsidiaries.
  • The damages relating to the Almaden and Almadex Claim will be for no less than US$200 million, in the aggregate.
  • Although Almaden has requested consultations with Mexico under the CPTPP, to date Mexico has not proposed a date for these consultations.

EudraVigilance registration documents

Retrieved on: 
Wednesday, April 3, 2024
Community, Reproduction, EV, EudraVigilance, Annex, Letter, Regulation (European Union), European Parliament, Qualified person (European Union), Regulation, RP, OMS, EMA, Commercial, Request, Law, Marketing, European Medicines Agency, MAH, Council, EEA, Service, European, Clinical trial, ID, User, Register, Security printing

Table of contents

Key Points: 
    • Table of contents
      Pre-requisites .............................................................................................. 3
      Registration of the headquarter for Marketing Authorisation Holders
      (MAHs) ........................................................................................................ 3
      Registration of the headquarter for Commercial and Non-commercial
      sponsors ...................................................................................................... 4
      Registration of the headquarter of National Competent Authorities ............ 5

      EudraVigilance registration documents
      EMA/503894/2018

      Page 2/5

      Pre-requisites
      ?

      User registration in the EMA Account Management Portal ? see section 2.1 of the EudraVigilance
      Registration Manual.

    • ?

      Registration of the organisation in the Organisation Management System ? see section 3.3 of the
      EudraVigilance Registration Manual.

    • ?

      Request of the role, as applicable, ?EV MAH EU QPPV? or ?EV NCA Responsible? or ?EV CS/NCS
      Responsible? by the user via the EMA Account Management Portal ? see section 5.2 and Annex
      1 of the EudraVigilance Registration Manual.

    • ?

      Once the role has been requested in the EMA Account Management Portal, a Service Desk ticket
      should be raised to the Registration team, quoting the Request ID number and attaching the
      required documents listed below.

    • Registration of the headquarter for Marketing Authorisation
      Holders (MAHs)
      ?

      A cover letter from the headquarters level of the organisation on a company?s headed paper.

    • EudraVigilance registration documents
      EMA/503894/2018

      Page 3/5

      profile who has completed the courses and is related to the respective organisation.

    • Registration of the headquarter for Commercial and
      Non-commercial sponsors
      ?

      A cover letter from the headquarters level of the organisation on a company?s headed paper.

    • EudraVigilance registration documents
      EMA/503894/2018

      Page 4/5

      Registration of the headquarter of National Competent
      Authorities
      ?

      A cover letter on organisation?s headed paper.

GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise

Retrieved on: 
Thursday, March 7, 2024
Infectious Diseases, General Health, Health, Other Health, Inflation, Senior, Immunization, GSK, Education, Physician, Hope, Entrepreneurship, Vaccine, Vaccination, American Lung Association, Patient, Request, IRA, Health equity, Infection, Medicaid, GSK plc, Pharmaceutical industry

GSK plc (LSE/NYSE: GSK) today announced additional funding and new data and resources under the COiMMUNITY Initiative to help achieve higher adult vaccination rates and health equity in the US and address ongoing barriers to adult immunization.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) today announced additional funding and new data and resources under the COiMMUNITY Initiative to help achieve higher adult vaccination rates and health equity in the US and address ongoing barriers to adult immunization.
  • The COiMMUNITY Initiative complements recent industry and regulatory efforts to expand and improve adult vaccine availability, coverage and access.
  • GSK is equipping healthcare providers and their patients with simple tools to spur action and follow through on vaccination.
  • GSK will also continue to share new resources, tools and best practices in adult vaccine confidence and delivery via interactive webinars.

NCPDP Foundation Opens Its Call for Grant Proposals, Due April 30

Retrieved on: 
Wednesday, February 28, 2024
Innovation, Digital therapeutics, Pharmacogenomics, Social, Pharmacist, Chesley Bonestell, MST, Health, Patient safety, Fund, Medicine, HL7, Trustee, Arrangement, Request, Standard, Value, Role, Single-frequency network, Health equity, Pharmaceutical industry

SCOTTSDALE, Ariz., Feb. 28, 2024 /PRNewswire-PRWeb/ -- The NCPDP Foundation Board of Trustees announced its call for grant proposals that demonstrate the value of NCPDP standards in supporting the expanded role of pharmacists, patient safety, access to care, and coordination of care and innovation. Proposals must meet the grant proposal requirements and be submitted electronically by 5:00 p.m. MST on April 30, 2024, to be considered for the current grant funding cycle.

Key Points: 
  • SCOTTSDALE, Ariz., Feb. 28, 2024 /PRNewswire-PRWeb/ -- The NCPDP Foundation Board of Trustees announced its call for grant proposals that demonstrate the value of NCPDP standards in supporting the expanded role of pharmacists, patient safety, access to care, and coordination of care and innovation.
  • Proposals must meet the grant proposal requirements and be submitted electronically by 5:00 p.m. MST on April 30, 2024, to be considered for the current grant funding cycle.
  • Grant projects must benefit at least one of the NCPDP Foundation strategic initiatives: expanding the role and value of the pharmacist ; expanding patient access to care ; enhancing patient safety ; and empowering coordination of care and innovation, its newest strategic initiative.
  • To submit a grant proposal, complete and submit the Request for Funding form along with supplemental material by 5:00 p.m. MST on April 30, 2024.

Campbell and Sovos Brands Certify Substantial Compliance with Second Request from FTC; Begins the Start of 30-Day Waiting Period

Retrieved on: 
Tuesday, February 13, 2024
Acquisition, FTC, Campbell Soup Company, Second request, Sale, CPB, Certification, Federal Trade Commission, Request

CAMDEN, N.J. and LOUISVILLE, Colo., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Campbell Soup Company (NYSE: CPB) and Sovos Brands, Inc. (NASDAQ: SOVO) today announced that both companies have certified substantial compliance with the Request for Additional Information and Documentary Materials ("Second Request") issued by the Federal Trade Commission (FTC) regarding Campbell’s proposed acquisition of Sovos Brands.

Key Points: 
  • CAMDEN, N.J. and LOUISVILLE, Colo., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Campbell Soup Company (NYSE: CPB) and Sovos Brands, Inc. (NASDAQ: SOVO) today announced that both companies have certified substantial compliance with the Request for Additional Information and Documentary Materials ("Second Request") issued by the Federal Trade Commission (FTC) regarding Campbell’s proposed acquisition of Sovos Brands.
  • The certification of substantial compliance triggers the start of a 30-day waiting period which is expected to expire on March 11, 2024, after which the sale can be finalized.
  • Subject to the satisfaction or waiver of customary closing conditions, the companies expect to complete the transaction within days of the March 11, 2024 expiration date.
  • “We’re excited to be one step closer to completing the acquisition and welcoming the talented Sovos Brands employees to Campbell’s team,” said Campbell’s President and CEO Mark Clouse.

Campbell and Sovos Brands Certify Substantial Compliance with Second Request from FTC; Begins the Start of 30-Day Waiting Period

Retrieved on: 
Tuesday, February 13, 2024
Supermarket, Retail, Convenience Store, Food, Beverage, Acquisition, FTC, Multimedia, Campbell Soup Company, Second request, Sale, CPB, Certification, Federal Trade Commission, Request

Campbell Soup Company (NYSE: CPB) and Sovos Brands, Inc. (NASDAQ: SOVO) today announced that both companies have certified substantial compliance with the Request for Additional Information and Documentary Materials ("Second Request") issued by the Federal Trade Commission (FTC) regarding Campbell’s proposed acquisition of Sovos Brands.

Key Points: 
  • Campbell Soup Company (NYSE: CPB) and Sovos Brands, Inc. (NASDAQ: SOVO) today announced that both companies have certified substantial compliance with the Request for Additional Information and Documentary Materials ("Second Request") issued by the Federal Trade Commission (FTC) regarding Campbell’s proposed acquisition of Sovos Brands.
  • View the full release here: https://www.businesswire.com/news/home/20240213296929/en/
    The certification of substantial compliance triggers the start of a 30-day waiting period which is expected to expire on March 11, 2024, after which the sale can be finalized.
  • Subject to the satisfaction or waiver of customary closing conditions, the companies expect to complete the transaction within days of the March 11, 2024 expiration date.
  • “We’re excited to be one step closer to completing the acquisition and welcoming the talented Sovos Brands employees to Campbell’s team,” said Campbell’s President and CEO Mark Clouse.

Rehabtronics Selected by Praxis Spinal Cord Institute to Launch Prelivia Pilot Program with Providence Health Care Ventures, Pioneering Innovative Solutions to Combat Pressure Injuries

Retrieved on: 
Tuesday, February 6, 2024
Providence Healthcare, Pressure, Research, Patient, CDE, MedlinePlus, Paralysis, Tetraplegia, Commercialization, RFP, Risk, SCI, Request, RN, Management

Pressure injuries are a common medical complication of paralysis and immobility, and people living with Spinal Cord Injuries (SCI) are at an elevated risk of developing them.

Key Points: 
  • Pressure injuries are a common medical complication of paralysis and immobility, and people living with Spinal Cord Injuries (SCI) are at an elevated risk of developing them.
  • Praxis Spinal Cord Institute, a global leader in spinal cord injury research and innovation, has recognized the expertise and commitment of Rehabtronics in advancing technology related to pressure injuries for people with SCI.
  • "We are thrilled to be selected by the Praxis Spinal Cord Institute for this important initiative," said Rahul Samant, CEO at Rehabtronics.
  • We look forward to working with the Praxis Spinal Cord Institute and Providence Health Care Ventures in accomplishing our shared vision of transforming pressure injury care."

MTF Biologics Awards 2023 Grants for Innovation in Allograft Translational Research

Retrieved on: 
Monday, January 22, 2024
Health, Surgery, General Health, Research, Science, Biotechnology, Intellectual property, Sports medicine, Letter, Proposal, Transplant, Request, Spine, Elective surgery, Purdue University, Transport, Doctor of Philosophy, EVP, MTF, Pharmaceutical industry

“MTF Biologics is proud of our long-standing commitment to supporting the scientific and patient communities through our allograft innovation grants,” said Joe Yaccarino, President and CEO of MTF Biologics.

Key Points: 
  • “MTF Biologics is proud of our long-standing commitment to supporting the scientific and patient communities through our allograft innovation grants,” said Joe Yaccarino, President and CEO of MTF Biologics.
  • “These grants advance the science of allograft tissue transportation and support MTF Biologics’ dedication to saving and healing lives.
  • We congratulate all of this year's recipients and look forward to the results of their crucial work which will positively impact lives around the world.”
    Innovation in Allograft Translational Research Grants fund translational and clinical research in the fields of allograft transplantation and allograft science.
  • Hans Burchardt Impact Awardee” for the awarded grant with the highest potential clinical impact.”
    Letters of Intent are now being accepted for the 2024 MTF Biologics Innovation in Allograft Translational Research Grants Program.

LUNGevity and Hamoui Foundations Issue RFA for Research Into RET-positive Lung Cancer

Retrieved on: 
Thursday, January 25, 2024
Patient, Thought, Research, Drug resistance, Partnership, Request, Lung cancer, RET, NSCLC, Disease, FDA, MPH, Pharmaceutical industry

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to announce its second partnership with the Hamoui Foundation to issue an RFA (Request for Application) for the Hamoui Foundation/LUNGevity Clinical Research Award for RET-positive Lung Cancer.

Key Points: 
  • WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to announce its second partnership with the Hamoui Foundation to issue an RFA (Request for Application) for the Hamoui Foundation/LUNGevity Clinical Research Award for RET-positive Lung Cancer.
  • The Hamoui Foundation/LUNGevity RET-positive Award aims to address this gap by funding research to improve outcomes for patients with RET-positive lung cancer.
  • "In 2021, when we announced our first partnership with Hamoui Foundation, it was clear that without philanthropic funding in this area, the research would not happen," said Upal Basu Roy, PhD, MPH, executive director of LUNGevity Research.
  • "We awarded $1 million in research grants to gain insights into understanding non-genomic mechanisms of drug resistance in RET-positive lung cancer, leveraging existing FDA-approved drugs to treat RET-positive lung cancer, and studying the structural changes to altered RET proteins.

LUNGevity Foundation Issues 12th Annual RFA for Career Development Awards in Support of Lung Cancer Workforce

Retrieved on: 
Thursday, January 25, 2024
Research, MD, Request, Lung cancer, Immunotherapy, MBA, Laboratory, FDA, Doctor of Philosophy, Workforce, MPH, Nursing

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is proud to issue an RFA (Request for Application) for the Career Development Award program.

Key Points: 
  • WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is proud to issue an RFA (Request for Application) for the Career Development Award program.
  • "Today, the awards are often considered a rite of passage for early-career researchers interested in studying lung cancer."
  • LUNGevity is pleased to announce its second year of partnering with Lung Cancer Initiative to support these important awards.
  • For more information on this RFA, please visit Applying for a LUNGevity Award | LUNGevity Foundation .